Scenario and Alternative Future

A scenario planning approach does not attempt to predict a single potential future, but rather plans for several hypothetical but plausible futures. In this direction, the assessment methodically examines the four scenario frameworks to derive the most basic constructs and uses. In the Day and Schoemaker (2005) model, the focus is on scanning the peripheral signals in order to perceive newer changes as they emerge. Hussain, Tapinos and Knight (2017) demonstrate the possibility of merging the two approaches, but through scenario planning, the weaknesses of technology roadmapping can be addressed. Ramirez et al. (2017) recommend thinking about the potential situations in stormy periods to redefine the strategy of an organisation. Scenarios are given by Godet and Roubelat (1996) as images of possible futures and the connectivity between the present situation and the possible futures. The synthesis matrix was done in 5 phases as evaluated key points of each article, identifying key constructs, completing article cells, identifying cross-article themes, and synthesizing findings, which were done methodologically. Several parameters, including the approaches to scanning the surroundings, the ways of developing scenarios, and the strategic ways of implementing each of the frameworks, were considered (Rozak et al., 2021). Comparative analysis in assessment provides a premise for the choice of the most suitable framework, which will be applied in the pharmaceutical industry.

Part 1: Scenario Synthesis

The four scenario frameworks are complementary approaches to organizational foresight that are different. The peripheral vision paradigm (Day and Schoemaker 2005) is the cognitive constraint in terms of the identification of weak signals. The French ‘prospective approach’ of Godet and Roubelat (1996) provided tools for analytical purposes that are rigorous in the development of the scenarios. A type of strategic foresight and technology planning was the scenario-based road mapping explained by Hussain et al. (2017). It was informed by the Oxford approach (Ramirez et al., 2017), which is founded on co-reframing believable scenarios. The similarities that unite all the frameworks are the common aim to promote strategic decision-making during times of uncertainty. The research works are different in relation to their approach to philosophy of teaching, methodological approach, and performance requirements. For successful scenario planning, it is important that the features and characteristics of the framework match the context and needs in the organization. The synthesis indicates that a mixture of the elements on the different structures can lead to greater effectiveness.

Table 1

Scenario Planning Frameworks Synthesis Matrix

Part 2: Scenario Framework for Pharmaceutical Industry

Selected Scenario Framework

The executives differentiate between the transactional environment and their contextual environment, thus isolating the parts of business they can control and those they cannot. The Oxford scenario planning model of MiracleDrugs analysis (Ramirez et al., 2017) is chosen. The framework is founded on plausibility rather than probability since, in a high-uncertainty environment, such as the pharmaceutical industry, it is the appropriate way of doing things. Joint reframing benefits companies to cope effectively with a turbulent environment, as discovered by Ramirez et al. (2017). The pharmaceutical industry has extremely high turbulence, uncertainty, novelty, and ambiguity (TUNA) pressures, which are regulation, technology, and market changes. Hussain et al. (2017) argue that scenario planning must take into account various eventualities, as opposed to single forecasts. Organizational learning can take place in the iterative nature of the Oxford approach, whereby there are multiple interactions with other futures. Day and Schoemaker (2005) concentrated on peripheral vision, but pharmaceutical executives need to conduct a full analysis of the environment outside the weak signals. The French prospective approach suggested by Godet and Roubelat (1996) implied that planning demands a lot of quantitative analysis, which is not appropriate in the beginning stage of strategic dialogues. Oxford framework integrates the rigor of analysis but also has exciting collaborative procedures for a range of executive teams.

The selected framework has these strategic advantages over others when used in the Pharmaceutical industry application. Ramirez et al. (2017) managed to implement the approach in the complex industry with a high rate of change. The reframing of the existing strategy will assist pharmaceutical executives to begin to question the assumptions made about markets. Jeong et al. (2021) suggest road mapping by scenario as giving technological integration, but no complexity is required at the first level of strategic planning. The Oxford method is laborious, and pharmaceutical firms can afford to spend time on such crucial decisions as long-term ones. Like in the pharmaceutical industry case, patenting is a lengthy process (10 years), there are plenty of phases involved, and you require a structure that has longer perspectives. Miller et al. (2022) highlighted collaboration and creating a consensus between executives, who have diversified functional experiences and views. The building’s design will optimize MiracleDrugs’ ability to craft effective strategies that are more than one viable pharmaceutical future.

Current State Pharmaceutical Industry Trends and Performance Indicators

The pharmaceutical industry is under the influence of five major trends that impact scenario development and are currently affecting the pharmaceutical industry. First, there is patent cliff pressure, as big blockbuster drugs go generic and cause revenue streams to be under pressure. The trend, as indicated, indicates the number of mergers and acquisitions being carried out to fill the empty pipelines and remain profitable. Second, with the advent of personalized medicine and precision therapeutics, the development of genomics and finding biomarkers makes the process faster. Hällerstrand et al. (2023) emphasized the need to scan the emerging technologies that have the potential to transform the competitive landscape in the industry radically. The transition suggests reduced patient groups and increased prices of drugs, and more focused research investments. Third, the regulatory complexity is increasing around the world as major markets such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have divergent approval pathways (Car et al., 2025). Fourth is the incorporation of digital health due to AI, real-world evidence, and the ability to monitor patients remotely. Longer timelines to market access, thus higher cost of compliance, impact development strategy and resource allocation decisions.

Clinical trial plans, post-market surveillance, and patient engagement models are also models that can be transformed with the aid of digitalization. Lastly, prices are subject to governmental price negotiation, payer negotiation, and social criticism of drug pricing. Godet and Roubelat (1996) pointed out that the construction of scenarios should be able to react to the economic forces affecting the sustainability of the industry. It can also be applied to value-based pricing models, outcomes-based contracts, and pharmaceutical business model innovation. The five trends are major uncertainties to be taken into consideration by pharmaceutical executives in the 10-year scenario planning. Each of the trends is associated with various degrees of ambiguity and potential impact on the performance and strategy of organizations (Allan and Alghizzawi, 2024). The trends’ interrelationships form complexities that need an organized investigation by formal scenario frameworks.

Trigger Questions for Executive Team

Five thought-provoking trigger questions will be used that will make executives in MiracleDrugs think 10-years about pharmaceutical situations.

1. What happens when AIs can discover and develop new medicines faster than conventional R&D?
2. What about the price controls that are obligatory and can be introduced by governments in all the major pharmaceutical markets across the globe?
3. What is the effect of personal medicine whereby blockbuster drugs in the next five years are not utilized?
4. What are the possible consequences if over the next 10 years 60% of the market share of biologics goes to biosimilars?
5. What would happen in case of a direct-to-consumer genetic test and a doctor visits them through telemedicine to prescribe a medication?

The pharmaceutical industry nowadays is a physician-prescriptive industry where it has no direct interaction with the patient or sales. The ownership of health data and access to telehealth can disrupt the typical distribution and marketing system, putting consumers in charge (Burrell, 2024). The question poses doubts regarding customer relations, marketing expenditures, and regulatory compliance on access to pharmaceuticals.

Conclusion

Pharmaceutical executives need the tools to cope with unprecedented uncertainty and change in their industry, and that’s what scenario planning provides. The evaluation took into account four scenario frames, as well as the environmental scanning approach, stakeholder approach, and uncertainty approach. In the context of the 10-year futures analysis on MiracleDrugs, where the analysis was based on plausibility in turbulent times, the Oxford approach of scenario planning was the most appropriate of the three approaches. The scenario is developed on the five major trends that include patent cliffs, personalized medicine, regulatory complexity, integration with digital health, and pricing pressures. The five trigger questions created put basic assumptions in the pharmaceutical industry on drug discovery, pricing models, and market penetration to the test.